U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2003

[ ]  TRANSITION  REPORT  UNDER  SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE
     ACT OF 1934 FOR THE TRANSITION PERIOD FROM           TO


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                    98-0178784
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)


       #3-1482 Springfield Road, Kelowna, British Columbia, Canada V1Y 5V3
                    (Address of principal executive offices)

                                  250.762.7552
                (Issuer's Telephone Number, including Area Code)


                              Thomas E. Stepp, Jr.
                                 Stepp Law Group
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements for the past 90 days.
[X] Yes [ ] No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date. As of February 28, 2003,  there were
6,308,989  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>










                                     PART I
                                     ------

Item 1.  Financial Statements
-----------------------------








                        Consolidated Financial Statements of


                        L.O.M. MEDICAL INTERNATIONAL INC.

                        (A Development Stage Enterprise)

                        Nine months ended February 28, 2003

                        (Unaudited)































<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheets
$ United States

February 28, 2003 and May 31, 2002

=====================================================================================================
                                                                     February 28,          May 31,
                                                                             2003             2002
                                                                      (Unaudited)
-----------------------------------------------------------------------------------------------------

Assets
------

<S>                                                                <C>               <C>
Current assets:
     Cash and cash equivalents                                     $       21,557    $     142,114
     Amounts receivable                                                    12,313           18,933
     Prepaid expenses                                                      14,485            8,235
     ------------------------------------------------------------------------------------------------
                                                                           48,355          169,282

Advances and deposits                                                       9,803            9,803

Fixed assets                                                               19,558           28,564

Patent costs                                                                1,042            4,168

-----------------------------------------------------------------------------------------------------
                                                                   $       78,758    $     211,817
=====================================================================================================

Liabilities and Stockholders' Deficiency
----------------------------------------

Current liabilities:
     Accounts payable and accrued liabilities (note 2 (a))         $      288,709    $     319,537
     Convertible promissory notes (note 3)                                 32,675             -
-----------------------------------------------------------------------------------------------------
                                                                          321,384          319,537

Minority interest                                                         296,328          288,491

Share subscriptions (note 4)                                                8,772           34,375

Stockholders' deficiency:
     Capital stock
       5,000,000 preferred shares with a par value of $0.001 per
          share authorized
       50,000,000  common shares with a par value of $0.001 per
          share authorized,  6,308,989 issued (May 31, 2002 -
          6,178,446  issued),  net of  treasury  stock of 52,073
          (May 31, 2002 - 84,436)                                           6,310            6,179
     Additional paid-in capital                                         4,068,219        3,464,159
     Deficit accumulated during the development stage                  (4,655,559)      (3,934,228)
     Accumulated other comprehensive income                                33,304           33,304
     ------------------------------------------------------------------------------------------------
                                                                         (547,726)        (430,586)
Going concern (note 1 (a))
Commitments (note 2 (b))
-----------------------------------------------------------------------------------------------------
                                                                   $       78,758    $     211,817
=====================================================================================================
</TABLE>

See accompanying notes to consolidated financial statements




<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Nine months ended February 28, 2003 and 2002 and period from inception (March
17, 1997) to February 28, 2003
(Unaudited)

=========================================================================================================
                                                 From inception        Nine months ended, February 28,
                                               (March 17, 1997)        -------------------------------
                                           to February 28, 2003               2003                2002
---------------------------------------------------------------------------------------------------------

<S>                                          <C>                     <C>                 <C>
Expenses:
     General and administration              $        3,409,310      $     646,342       $     459,279
     Research and development                         1,369,062             75,556             383,163
     ----------------------------------------------------------------------------------------------------
                                                      4,778,372            721,898             842,442

---------------------------------------------------------------------------------------------------------
Loss from operations                                 (4,778,372)          (721,898)           (842,442)

Other income:
     Interest income                                    122,813                567               7,611

---------------------------------------------------------------------------------------------------------
Loss                                         $       (4,655,559)     $    (721,331)      $    (834,831)
=========================================================================================================


Weighted average number of common shares,
   basic and diluted                                  5,158,632          6,226,941           6,154,380

Loss per share, basic and diluted            $            (0.90)     $       (0.12)      $       (0.14)
=========================================================================================================
</TABLE>

See accompanying notes to consolidated financial statements




<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Three months ended February 28, 2003 and 2002
(Unaudited)

================================================================================
                                                        2003             2002
--------------------------------------------------------------------------------

Expenses:
     General and administration               $      356,072    $     223,502
     Research and development                         25,323            3,945
     ---------------------------------------------------------------------------
                                                     381,395          227,447

--------------------------------------------------------------------------------
Loss from operations                                (381,395)        (227,447)

Other income:
     Interest income                                      55              476

--------------------------------------------------------------------------------
Loss                                          $     (381,340)   $    (226,971)
================================================================================


Weighted average number of common shares,
   basic and diluted                               6,281,523        6,129,467

Loss per common share, basic and diluted      $        (0.06)   $       (0.04)
================================================================================

See accompanying notes to consolidated financial statements




<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows
($ United States)

Nine months ended February 28, 2003 and 2002 and period from inception (March
17, 1997) to February 28, 2003
(Unaudited)

==================================================================================================================================
                                                                             From inception         Nine months ended February 28,
                                                                           (March 17, 1997)         ------------------------------
                                                                       to February 28, 2003               2003                2002
----------------------------------------------------------------------------------------------------------------------------------

<S>                                                                      <C>                     <C>                 <C>
Operating activities:
   Net Loss for the period                                               $       (4,655,559)     $    (721,331)      $    (834,831)

   Items not involving cash
     Amortization                                                                    97,377             12,132              13,910
     Amortization of discount on convertible promissory notes                         8,974              8,974                   -
     Gain on sale of fixed assets                                                    (2,659)                 -                   -
     Write down of product rights and patent costs                                  374,128                  -                   -
     Subscription for common shares for consulting services                           3,250              3,250                   -
     Common shares issued for consulting services                                   106,334             88,734                   -
     Compensation cost of stock options issued for services (note 5)                486,719            191,450                   -
     Foreign exchange gain on redeemable preferred
       shares                                                                        (5,399)             7,837             (27,114)
     Write-down of advances and deposits                                            168,680                  -             114,000

   Changes in non-cash working capital
     Amounts receivable                                                             (12,313)             6,620              14,155
     Prepaid expenses                                                               (14,485)            (6,250)             (8,746)
     Accounts payable and accrued liabilities                                       123,529             28,190             (57,517)
     -------------------------------------------------------------------------------------------------------------------------------
                                                                                 (3,321,424)          (380,394)           (786,143)
Financing activities:
     Issuance of capital stock                                                    2,741,872            188,323             259,148
     Issuance of convertible debentures                                              66,639             66,639                   -
     Common shares rescinded or repurchased                                         (47,226)                 -             (47,226)
     Proceeds from subscriptions for shares                                         914,594              4,875              45,926
     -------------------------------------------------------------------------------------------------------------------------------
                                                                                  3,675,879            259,837             257,848
Investing activities:
     Advances and deposits                                                         (178,483)                 -             (16,408)
     Proceeds on disposition of fixed assets                                          6,189                  -                   -
     Acquisition of fixed assets                                                   (103,508)                 -              (2,278)
     Acquisition of product rights                                                  (90,577)                 -                   -
     -------------------------------------------------------------------------------------------------------------------------------
                                                                                   (366,379)                 -             (18,686)

Effects of change in exchange rates on cash and cash equivalents                     33,481                  -                   -
------------------------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash and cash equivalents                                     21,557           (120,557)           (546,981)

Cash and cash equivalents, beginning of period                                           -             142,114             741,152
------------------------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents, end of period                                 $           21,557      $      21,557       $     194,171
====================================================================================================================================



<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows (continued)
($ United States)

Nine months ended February 28, 2003 and 2002 and period from inception (March
17, 1997) to February 28, 2003
(Unaudited)

====================================================================================================================================

<S>                                                                      <C>                     <C>                   <C>
Supplementary information
   Interest paid                                                         $                -      $           -         $         -
   Income taxes paid                                                                      -                  -                   -
Non-cash financing and investing activities
   Issuance of redeemable preferred shares for product rights                       309,677                  -                   -
   Common shares issued for conversion of share subscriptions                       909,719             34,375              22,100
   Common shares issued for consulting services                                     106,334             88,734                   -
   Common shares rescinded and cancelled                                             46,226                  -                   -
   Subscriptions for common shares for consulting services                            3,250              3,250                   -
   Common shares issued upon conversion of convertible promissory
     notes                                                                              646                646                   -
   Subscriptions for common shares upon conversion of convertible
     promissory notes                                                                   647                647                   -
   Compensation cost of stock options issued for services (note 5)                  486,719            191,450                   -
   Unpaid amount related to rescinded shares (note 2 (a))                           158,334            (59,013)            216,597
   Unpaid amount related to returned shares                                           6,851                  -                   -
====================================================================================================================================
</TABLE>

See accompanying notes to consolidated financial statements


<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Stockholders' Equity (Deficiency) and Comprehensive
Loss
$ United States

Period from inception (March 17, 1997) to February 28, 2003

====================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated          Total
                                             Number                Additional    During the           Other  Stockholders'
                                          of Common                   Paid in   Development   Comprehensive         Equity
                                             Shares      Amount       Capital         Stage          Income   (Deficiency)
------------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Common shares issued on incorporation             3  $        1  $          -  $          -  $            -  $           1

Comprehensive income (loss):
  Loss                                            -           -             -      (138,272)              -       (138,272)
  Foreign currency translation                    -           -             -             -          13,582         13,582
------------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                (124,690)

------------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                             3           1             -      (138,272)         13,582       (124,689)

Common shares issued to founders
  and others at $0.001                    4,210,090       4,210             -             -               -          4,210

Common shares issued at $1.00
  net of share issue costs                  668,154         668       469,887             -               -        470,555

Common shares issued at $1.00 on
  conversion of share subscriptions         605,000         605       604,395             -               -        605,000

Comprehensive income (loss):
  Loss                                            -           -             -      (293,239)              -       (293,239)
  Foreign currency translation                    -           -             -             -           (7,294)       (7,294)
------------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                               (300,533)

------------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998                     5,483,247       5,484     1,074,282     (431,511)           6,288        654,543

Common shares issued on
  November 30, 1998 at $3.25
  net of share issue costs                   36,300          36        96,726             -               -         96,762

Comprehensive income (loss):
  Loss                                            -           -             -      (726,055)              -       (726,055)
  Foreign currency translation                    -           -             -             -          17,038         17,038
------------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                (709,017)

------------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999                     5,519,547       5,520     1,171,008    (1,157,566)         23,326         42,288

Common shares issued on
  April 17, 2000 at $3.25
  net of share issue costs                  307,610         308       967,335             -               -        967,643

Common shares issued on
  May 10, 2000 at $3.25 on
  conversion of share
  subscriptions                              19,302          19        62,712             -               -         62,731

Comprehensive income (loss):
  Loss                                            -           -             -      (508,835)              -       (508,835)
  Foreign currency translation                    -           -             -             -           9,978          9,978
------------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                (498,857)

------------------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2000                     5,846,459  $    5,847  $  2,201,055  $ (1,666,401) $       33,304  $     573,805
====================================================================================================================================





<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity (Deficiency) and Comprehensive
Income (continued)
$ United States

For the period from inception (March 17, 1997) to February 28, 2003

====================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated          Total
                                             Number                Additional    During the           Other  Stockholders'
                                          of Common                   Paid in   Development   Comprehensive         Equity
                                             Shares      Amount       Capital         Stage          Income   (Deficiency)
------------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Balance, May 31, 2000,
  carried forward                         5,846,459  $    5,847  $  2,201,055  $(1,666,401)  $       33,304  $     573,805

Common shares issued on
  September 22, 2000 for
  cash at $3.25 net of share
  issue costs                               249,271         250       726,654             -               -        726,904

Common shares issued on
  December 19, 2000 at $3.25
  on conversion of share
  subscriptions                              57,081          57       185,456             -               -        185,513

Compensation costs for
  stock options issued for
  services                                        -           -       295,269             -               -        295,269

Comprehensive income (loss):
  Loss                                            -           -             -    (1,216,128)              -     (1,216,128)
  Foreign currency translation                    -           -             -             -               -              -
------------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                              (1,216,128)

------------------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2001                     6,152,811       6,154     3,408,434    (2,882,529)         33,304        565,363

Common shares issued on
  August 31, 2001 at $3.25
  on conversion of share
  subscriptions                               6,800           7        22,093             -               -         22,100

Common shares issued for cash
  on October 11, 2001 at $3.25, net
  of share issue costs                       38,211          38       110,245             -               -        110,283

Common shares issued for cash
  on January 10, 2002 at $3.25                5,020           5        16,310             -               -         16,315

Common shares issued for cash
  on January 10, 2002 at $2.41               47,697          47       114,903             -               -        114,950

Common shares issued for consulting
  services rendered on January 10, 2002
  at $2.41                                    7,303           7        17,593             -               -         17,600

Shares rescinded and cancelled
  on February 22, 2002                      (18,702)        (19)      (46,207)            -               -        (46,226)

Common shares issued for cash
  on April 2, 2002 at $3.25                   2,880           3         9,357             -               -          9,360

Common shares issued for cash
  on April 2, 2002 at $2.41                  10,400          10        25,054             -               -         25,064



<PAGE>

<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity (Deficiency) and Comprehensive
Income (continued)
$ United States

Period from inception (March 17, 1997) to February 28, 2003

====================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated          Total
                                             Number                Additional    During the           Other  Stockholders'
                                          of Common                   Paid in   Development   Comprehensive         Equity
                                             Shares      Amount       Capital         Stage          Income   (Deficiency)
------------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Common shares issued for cash
  on April 2, 2002 at $1.00                  10,000          10         9,990             -               -         10,000

Common shares issued for cash
  on April 24, 2002 at $3.25                    462           1         1,501             -               -          1,502

Comprehensive loss                                -           -             -    (1,051,699)              -     (1,051,699)
------------------------------------------------------------------------------------------------------------------------------------
                                          6,262,882       6,263     3,689,273    (3,934,228)         33,304       (205,388)
Shares rescinded and retained
  as treasury stock                         (81,231)        (81)     (217,266)            -               -       (217,347)
Shares repurchased and retained
  as treasury stock                          (3,205)         (3)       (7,848)            -               -         (7,851)
------------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2002                     6,178,446       6,179     3,464,159    (3,934,228)         33,304       (430,586)

Common shares issued on conversion
  of share subscriptions on
  August 30, 2002 at $3.25, net
  of share issue costs                       10,693          11        34,364             -               -         34,375

Common shares issued for cash on
  October 29, 2002 at $2.485                    165           -           410             -               -            410

Common shares issued for cash on
  October 29, 2002 at $2.61, net
  of share issue costs                       16,935          17        44,183             -               -         44,200

Common shares issued for cash on
  October 29, 2002 at $2.70, net
  of share issue costs                       14,923          15        40,275             -               -         40,290

Common shares issued for cash on
  October 29, 2002 at $3.25                     500           -         1,625             -               -          1,625

Common shares issued for cash on
  October 29, 2002 at $4.40                  14,546          15        63,985             -               -         64,000

Common shares issued for consulting
  services on October 29, 2002
  at $3.09                                   23,827          24        73,636             -               -         73,660

Common shares issued for cash on
  February 28, 2003 at $3.25                 11,630          12        37,786             -               -         37,798

Common shares issued for consulting
  services on February 28, 2003
  at $3.25                                    4,638           5        15,069             -               -         15,074

Common shares issued on
  February 28, 2003 at $2.00 upon
  conversion of convertible promissory
  note                                          323           -           646             -               -            646

Share rescission retracted (note 2 (a))      32,363          32        58,981             -               -         59,013

Beneficial conversion option
 on convertible promissory
  notes (note 3)                                  -           -        41,650             -               -         41,650

Compensation cost of options issued
  for services (note 5)                           -           -       191,450             -               -        191,450

Comprehensive loss:
  Loss                                            -           -             -      (721,331)              -       (721,331)
------------------------------------------------------------------------------------------------------------------------------------
Balance, February 28, 2003                6,308,989  $    6,310  $  4,068,219  $ (4,655,559) $       33,304  $    (547,726)
====================================================================================================================================
</TABLE>
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

Nine months ended February 28, 2003 and 2002
(Unaudited)

================================================================================

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new products in the medical field  including a retractable  syringe.  Operations
effectively commenced on June 1, 1997.

1.   Significant accounting policies:
-------------------------------------

     a)   Going concern

          These  financial  statements  have been  prepared by management on the
          going concern basis in accordance with accounting principles generally
          accepted  in  the  United   States  of  America,   which  assumes  the
          realization of assets and  liquidation of liabilities  and commitments
          in the  normal  course  of  business.  As  shown  in the  consolidated
          financial statements,  to date, the Company has generated no revenues,
          has a working  capital  deficiency and has accumulated a deficit since
          inception  of   $4,655,559.   These  factors,   among  others,   raise
          substantial  doubt about the Company's  ability to continue as a going
          concern.  The  Company's  ability to  continue  as a going  concern is
          dependent on its ability to generate future profitable  operations and
          receive  continued  financial  support from its stockholders and other
          investors.  The consolidated  financial  statements do not include any
          adjustments that might result from the outcome of this uncertainty.

          In the short-term,  management's  plans involve  obtaining  additional
          funding   from   stockholders   in  the  form  of   additional   share
          subscriptions  to support  continued  operations.  In the longer term,
          management's  plans include  generating future  profitable  operations
          from  future  sales  of  the  retractable  syringe.  There  can  be no
          assurance  that a market will develop for the  retractable  syringe or
          that additional share financings will be available.  Failure to obtain
          adequate  financing to continue  current  development  activities will
          cause the Company to curtail operations.

     b)   Basis of presentation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its wholly owned subsidiary. All significant inter-company
          balances and transactions have been eliminated.

          The financial  information  presented as at February 28, 2003, for the
          three and nine  months  ended  February  28, 2003 and 2002 and for the
          period  from  inception  (March  17,  1997) to  February  28,  2003 is
          unaudited,  however,  in the opinion of  management,  all  adjustments
          (consisting  solely of normal  recurring items) necessary for the fair
          presentation of these unaudited  amounts in conformity with accounting
          principles  generally  accepted in the United  States of America  have
          been made. These unaudited interim  consolidated  financial statements
          should be read in conjunction with the annual  consolidated  financial
          statements for the year ended May 31, 2002 filed under Form 10-KSB.

     c)   Management estimates

          The preparation of financial  statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management to make estimates and assumptions  that affect the reported
          amounts of assets and liabilities and disclosures of contingent assets
          and  liabilities  at the  date  of the  financial  statements  and the
          reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.


<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

Nine months ended February 28, 2003 and 2002
(Unaudited)

================================================================================

2.   Contingent liability:
--------------------------

     (a)  Stockholders  who  acquired  99,933 of common  stock from the  Company
          prior  to  May  31,  2001  for  aggregate  proceeds  of  approximately
          $263,573,  exercised  their right of rescission  during the year ended
          May 31, 2002.  As of February 28, 2003 the Company has repaid  $46,226
          of the $263,573.  In addition,  during the nine months ended  February
          28, 2003,  32,363 shares were retracted  from the rescission  offer by
          the original  purchasers,  resulting in a decrease in the liability of
          $59,013.  These shares were  returned to the  shareholder  and removed
          from treasury stock. The remaining $158,334 as at February 28, 2003 is
          unsecured and is included in accounts payable and accrued  liabilities
          on  the  consolidated   balance  sheet.  The  Company  does  not  have
          sufficient funds to repay this liability at this time.

          Treasury   stock  consists  of  the  99,933  shares  of  common  stock
          originally  acquired under the rescission  order less 18,702 shares of
          common stock that was  cancelled and 32,363 shares of common stock for
          which the  rescission  offer was  retracted by the original  purchaser
          plus 3,205 shares which were repurchased separately and are being held
          as treasury stock for total treasury stock of 52,073 shares.

     (b)  The Company has signed an offer to purchase  additional  office  space
          for  approximately  $604,000 with a planned occupancy date of April 1,
          2003. To date the Company has not secured the  necessary  financing to
          fund  this  acquisition.  It is not  currently  the  intention  of the
          Company to complete this transaction. As management's best estimate is
          that no  liability  will  arise  to the  Company  as a  result  of not
          completing  this offer to purchase,  no liability  has been accrued in
          these consolidated financial statements.

3.   Convertible promissory notes:
----------------------------------

     During  the nine  months  ended  February  28,  2003,  the  Company  issued
     convertible  promissory  notes for aggregate cash proceeds of $66,639.  The
     convertible promissory notes bears interest at 7.25%, are unsecured and are
     due June 30, 2003.  The original  principal of the notes is  convertible to
     common shares at $2.00 per share.  Accrued and unpaid interest on the notes
     was not originally convertible to common shares, however during the quarter
     management  and the note holders  agreed to convert any unpaid  interest at
     the conversion date at $2.00 per share as well.

     A  deemed  discount  existed  at the  date  of  issue  of  the  convertible
     promissory  notes  due to a  beneficial  conversion  option,  as they  were
     convertible into common shares at a price that was less than the fair value
     of the  common  shares at the date of  issuance.  Accordingly,  the  deemed
     discount  due to the  beneficial  conversion  option  of  $41,650  is being
     amortized  over the period from the issuance  date to the first  conversion
     date of June 30, 2003.

     During the nine months ended February 28, 2003,  $1,288 of the  convertible
     promissory  notes plus  accrued  interest  were  converted  into 323 common
     shares and subscriptions for 324 common shares of the Company.

     ===========================================================================
     Convertible promissory notes                                $      65,351

     Unamortized discount related to the beneficial conversion
     option                                                            (32,676)

     ---------------------------------------------------------------------------
                                                                 $      32,675
     ===========================================================================


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

Nine months ended February 28, 2003 and 2002
(Unaudited)

================================================================================

4.   Share subscriptions:
-------------------------

     As at May 31, 2002, the Company had received share subscriptions for 10,693
     common  shares at $3.25 per share for net  proceeds of $34,375.  During the
     nine months ended  February 28, 2003,  the Company  issued these shares and
     received  additional share  subscriptions  for 1,500 common shares at $3.25
     per share for net  proceeds  of $4,875,  1,000  common  shares at $3.25 per
     share in exchange for services received prior to February 28, 2003 having a
     value of $3,250,  as well as 324 shares at a price of $2.00 upon receipt of
     a notice of conversion for a convertible  promissory  note plus interest of
     $647.  All  subscription  proceeds  were  received by the Company  prior to
     February 28, 2003 and were issued subsequent to February 28, 2003.

5.   Stock options:
-------------------

     During the nine months ended February 28, 2003, the Company granted 359,833
     common  share  stock  purchase  options.  124,333  of the  options  have an
     exercise price of $3.73 per share, while the remaining 235,500 options have
     an  exercise  price of $3.25 per share.  124,333 of the  options  expire on
     January 24, 2008, while the remaining 235,500 options expire on January 24,
     2013. All options are fully vested.

     71,750 of the options were granted to non-employees for services.  The fair
     value of the options of $191,450  was  determined  using the  Black-Scholes
     method  using the life of the  options  as the  expected  life,  volatility
     factor of 80%, risk free rate of 2.75% and no assumed dividend rate and has
     been included in the determination of the loss for the period.

     The Company applies APB Opinion No. 25 in accounting for its stock options.
     Had the Company determined compensation cost based on the fair value at the
     grant date for its employee  stock options  calculated  in accordance  with
     SFAS 123, the  Company's  loss for the nine months ended  February 28, 2003
     would have increased to the performa amounts indicated below:

     ===========================================================================
                                                                       2003
     ---------------------------------------------------------------------------

     Loss
        As reported                                               (721,331)
        Pro forma                                               (1,664,331)

     Loss per share
        As reported                                                  (0.12)
        Pro forma                                                    (0.27)

     ===========================================================================

     The fair value of $943,000 of the options  granted to employees  during the
     quarter was determined using the Black-Scholes method using the assumptions
     noted above.


<PAGE>



Item 2.  Management's Discussion and Analysis or Plan of Operation
------------------------------------------------------------------

THIS  ANNUAL  REPORT  SPECIFIES  FORWARD-LOOKING  STATEMENTS  OF OUR  MANAGEMENT
("FORWARD-LOOKING  STATEMENTS") INCLUDING,  WITHOUT LIMITATION,  FORWARD-LOOKING
STATEMENTS   REGARDING  OUR   EXPECTATIONS,   BELIEFS,   INTENTIONS  AND  FUTURE
STRATEGIES.   FORWARD-LOOKING   STATEMENTS  ARE  STATEMENTS  THAT  ESTIMATE  THE
HAPPENING   OF  FUTURE   EVENTS   AND  ARE  NOT  BASED  ON   HISTORICAL   FACTS.
FORWARD-LOOKING  STATEMENTS  MAY BE  IDENTIFIED  BY THE  USE OF  FORWARD-LOOKING
TERMINOLOGY,  SUCH AS "COULD",  "MAY", "WILL",  "EXPECT",  "SHALL",  "ESTIMATE",
"ANTICIPATE",  "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", "INTEND" OR SIMILAR
TERMS,   VARIATIONS  OF  THOSE  TERMS  OR  THE  NEGATIVE  OF  THOSE  TERMS.  THE
FORWARD-LOOKING  STATEMENTS  SPECIFIED IN THIS  QUARTERLY  REPORT FOR THE 10-QSB
HAVE BEEN COMPILED BY US ON THE BASIS OF  ASSUMPTIONS  MADE BY US AND CONSIDERED
BY US TO BE REASONABLE. OUR FUTURE OPERATING RESULTS, HOWEVER, ARE IMPOSSIBLE TO
PREDICT AND NO  REPRESENTATION,  GUARANTY,  OR  WARRANTY IS TO BE INFERRED  FROM
THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE  FORWARD-LOOKING  STATEMENTS  REPRESENT
ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT TO UNCERTAINTY AS TO POSSIBLE CHANGES
IN ECONOMIC,  LEGISLATIVE,  INDUSTRY, AND OTHER CIRCUMSTANCES.  AS A RESULT, THE
IDENTIFICATION AND INTERPRETATION OF DATA AND OTHER INFORMATION AND THEIR USE IN
DEVELOPING  AND SELECTING  ASSUMPTIONS  FROM AND AMONG  REASONABLE  ALTERNATIVES
REQUIRE THE EXERCISE OF JUDGMENT.  TO THE EXTENT THAT THE ASSUMED  EVENTS DO NOT
OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY FROM ANTICIPATED OR PROJECTED RESULTS,
AND,  ACCORDINGLY,  NO  OPINION  IS  EXPRESSED  ON THE  ACHIEVABILITY  OF  THOSE
FORWARD-LOOKING   STATEMENTS.  NO  ASSURANCE  CAN  BE  GIVEN  THAT  ANY  OF  THE
ASSUMPTIONS RELATING TO THE FORWARD-LOOKING  STATEMENTS SPECIFIED IN THIS REPORT
ARE ACCURATE,  AND WE ASSUME NO  OBLIGATION  TO UPDATE ANY SUCH  FORWARD-LOOKING
STATEMENTS.

Our Development
---------------

L.O.M.  Medical  International Inc. was incorporated in the State of Delaware on
March 17, 1997. Our executive  offices are located at #3-1482  Springfield Road,
Kelowna, B. C., Canada V1Y 5V3. Our telephone number is 250.762.7552.

For purposes of  clarification,  all dollar amounts  specified in this Quarterly
Report on Form  10-QSB are in the  currency  of the United  States.  Anytime the
symbol "CDN" is used, it refers to the currency of Canada.

Our Business
------------

We were  incorporated for the purpose of researching and developing  health care
products.  Our goal is to become an  innovator  and  provider  of a  retractable
syringe  ("Syringe")  and related  products and  technologies to the health care
market.  We have  successfully  patented and  licensed  products in 70 countries
including the United States and Canada and continue to maintain  these  patents.
We plan to develop  new and  improved  products  and  provide  the  health  care
industry with better, safer products throughout the world.

The Retractable Syringe
-----------------------

We believe the Syringe will change standard  disposal methods for used syringes.
The Syringe has been developed to function as a standard hypodermic syringe that
we believe is safer to the caregiver or health care worker.  We believe that the
Syringe's unique design will allow health care providers to avoid direct contact
with used needles. The Syringe is covered by United States Patent No. 5,868,713,
dated  February  9,  1999,  and  international  patents  have  been  filed in 84
different countries.





<PAGE>



Once the needle of the  Syringe is  injected,  the user  simply has to press the
plunger  top gently  with his or her thumb to  automatically  retract the needle
into its own sealed chamber. The needle is now hidden where it remains locked in
place and cannot be used  again.  The  Syringe  does not  require a health  care
worker  to use both  hands to  retract  the  needle  after it has been  used and
withdrawn  from the patient.  The Syringe will be produced in standard  industry
sizes from 1CC to 20 CC, inclusive.

We intend to promote  the Syringe as a safer and less  risk-oriented  instrument
for hospital  staff and health care  workers.  We are  optimistic  that doctors,
nurses,  and other health care workers will  recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contamination-prevention"  characteristics.  We currently  have no contracts to
sell the Syringe and there are no  guarantees  as to the  existence or timing of
any such contracts in the future.

We anticipate that the products and technologies that we develop will be offered
to distributors on a worldwide basis, with an initial emphasis in Canada and the
United  States.  We hope  that our new  product  and  technology  ideas  will be
generated through active dialogues among our potential customers and our network
of  scientific   advisors.   We  also  hope  to   participate  in  national  and
international   conferences   and  generate   reviews  in  selected   scientific
literature.

We interact with a network of scientific advisors within the industry, including
members of academic institutions,  as well as potential customers. We anticipate
that these  relationships  will enable us to identify the  specialized  needs of
those potential  customers and provide  innovative and  commercially  acceptable
products and  technologies.  At this time,  our  relationships  with  scientific
advisors and academic  institutions  are limited to advisory  relationships.  We
anticipate  testing the Syringe in  conjunction  with teaching  universities  in
Canada, Britain, and other constituents of the United Kingdom.

Our engineering  personnel are continuing the additional patenting of the L.O.M.
retractable syringe. We are ensuring that patents correctly protect every detail
pertaining  to the  syringe.  The  detailed  patenting  will  also  include  the
retraction  technology,  and  any  other  medical  device  that  the  retraction
technology incorporates.

Additional  modeling  and  testing  of the 3cc  syringe  have led to  additional
enhancements to the syringe. These enhancements have led to the reduction of the
length,  and the reduced complexity of the various parts.  Initially,  this task
was to eliminate any dead space in the syringe.  This proved to be successful as
well as enhanced  performance of the retraction process. The syringe now has the
same length and diameter as a conventional  syringe,  which is a requirement for
the end user.

The 3cc syringe is ready for production.  Other syringe sizes 1cc,  1.5cc,  2cc,
5cc, and 10cc are ready for prototyping.  The production moulds will be modified
to accommodate new sizes. The extensive designing of the syringe components have
utilized the shared parts  between all sizes,  thus  minimizing  overall cost of
total parts.

The Company has begun design  plans for an assembly  line to produce the syringe
in commercial quantities.  The plan is being developed jointly by management and
a consulting  engineer.  The assembly  line plan  contemplates  features such as
programmable robotic systems with machine vision technology and high speed parts
flexible feeder systems.  The Company is also  contemplating  injector  moulding
machines,  sterilization  units,  packaging  equipment and other components that
comprise  the  planned  assembly  line.  Such  plans  are  contingent  upon  the
availability of funding. There can be no assurance that the Company will be able
to access sufficient or suitable funding to complete its plans.

During  the  next  12  months  we  anticipate   increasing   our  staff  as  the
pre-production  of the  syringe  moves  forward.  Dr.  Simon  Wood has agreed to
supervise our research and development department.  Currently, he bills us on an
hourly basis for work completed.  There is no written  contract with him at this
time. We have  contracted  with Kevin Conway,  a mid-level  engineer for certain
services.  Mr.  Conway  performs  subcontract  work on an  hourly  basis.  He is
assisting with CAD-CAM requirements  relating to the development of the Syringe.
We have contracted with Jim MacLean to perform the duties of Vice President. Jim
will be  assisting  the  company in raising  capital for the  production  of the
retractable syringe.




<PAGE>



To satisfy our  financial  obligations  pursuant to agreements to which we are a
party  during  the next few  months we  require  additional  cash  resources  of
approximately  $450,000, not inclusive of any additional cash resources required
to commence manufacturing. From our inception on March 17, 1997, to February 28,
2003, we have incurred  $1,369,062  related to the  development  of the Syringe,
including the proof of concept prototype and molds for the test syringes.

We are not currently  producing  commercial  quantities of products or currently
supplying any services to any third  parties.  No assurance can be given that we
will, on a timely basis, be able to make the transition from  manufacturing test
quantities of the Syringe to commercial  production  quantities  successfully or
arrange for contract manufacturing.

We anticipate sub-contracting commercial production of the Syringe for the first
2 years. At the end of the second year of production,  we anticipate engaging in
significant   discussions  regarding  the  potential  construction  of  our  own
production facility. We recognize that the construction of a production facility
will be  contingent  upon us having  reached  our  sales,  financing  and profit
projections.

The Blood Collection System
---------------------------

We have  incorporated the retraction  technology into blood collection kits. The
L.O.M.  blood collection kit includes the holder,  retractable  needle, gas cell
and the  retraction  technology.  The Company has also  designed a winged  blood
collection retractable needle. The L.O.M. blood collection tubes compliment both
of these systems.

By using  either of these two systems,  the user is able to deliver  exceptional
patient care without  compromising  personal safety. The use of the L.O.M. blood
collection  system  requires  very  little  training  as it looks and feels like
conventional  systems and only requires the  retraction  technology to be easily
activated after the collection is complete. In both systems, the needle retracts
completely  into the unit and is locked while the user is  completely  protected
from needle stick injuries.

Patents for the L.O.M.  blood collection kits are currently being filed. We will
be commencing the prototyping phase shortly.

The Eye Care System
-------------------

We have  invented  and  developed an  insertion  and storage  device for contact
lenses  (the "Eye Care  System"),  which is a method of handling  and  inserting
contact lenses.

We have produced 33,000 units of our eye care inserters,  which will be used for
demonstrations.  As such, we have not inventoried the units but we have expensed
them in the  past  financial  statements.  We  currently  have  the  ability  to
subcontract  out for the  production  of  commercial  quantities of our eye care
products. We currently have dies with an output capacity of 150,000 units. There
is a second set of dies designed  that will have a 300,000 unit  capacity  which
would allow the  production of a total of 450,000 units of eye care products per
month.

We have FDA  approval  to market  our line of eye care  products  in the  United
States and the  necessary  Canadian  approval  to market  eye-care  products  in
Canada.  We are reviewing various contracts with third parties to market the Eye
Care System in Canada, as well as the United States.

We plan to focus our  activities  over the next twelve months on the  production
and introduction of the Syringe.  When that is finalized,  we will implement our
marketing plan for the Eye Care System products.

Skin Care Products
------------------

At this time we are reorganizing our approach to our skin care products. We will
not be pursuing this area aggressively until we are producing the Syringe.



<PAGE>



Genetic Patents
---------------

We are currently  negotiating  licensing  agreements  with the owners of various
patents on genetic vectors. As of February 28, 2003, we have advanced $54,680 to
the patent owners. Given the uncertainty  regarding the future recoverability of
these advances we wrote these advances off in our 2002 fiscal year.

Business of Our Subsidiary
--------------------------

There has been no activity in the subsidiary  this quarter.  For the foreseeable
future the subsidiary will be inactive.

Future Capital Requirements
---------------------------

We will require additional cash to implement our business strategies,  including
cash for payment of increased  operating  expenses and our existing  obligations
and commitments. No assurance can be given, however, that we will have access to
the capital  markets in the  future,  or that  financing  will be  available  on
acceptable  terms to satisfy our cash  requirements  necessary to implement  our
business  strategies.  The  inability  to access the  capital  markets or obtain
acceptable  financing  could have a material  adverse  effect on our  results of
operations and financial condition.

Our forecast of the period of time during which our financial  resources will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could vary as a result of a number
of factors.

We anticipate  having to raise  additional  capital  during the next 3 months in
order to develop,  promote, produce and distribute our proposed products as well
as satisfy our existing obligations, including the liability disclosed in note 2
to the  financial  statements.  Such  additional  capital may be raised  through
additional  public  or  private  financings,  as well as  borrowings  and  other
resources.  To the extent  that  additional  capital is raised  from the sale of
equity or  equity-related  securities,  the issuance of those  securities  could
result in dilution of our stockholders.

The Company has also signed an offer to  purchase  additional  office  space for
approximately  $604,000 with a planned  occupancy date of April 1, 2003. To date
the Company has not secured the necessary financing to fund this acquisition. It
is not  currently  the  intention of the Company to complete  this  transaction.
Management's  best  estimate is that no liability  will arise as a result of not
completing this offer to purchase.

There can be no assurance that additional funding will be available on favorable
terms, if at all. If adequate funds are not available  within the next 3 months,
we will be required to curtail  operations  significantly  or to obtain funds by
entering  into  arrangements  with  collaborative  partners  or others  that may
require us to  relinquish  rights to certain of our  products  that we would not
otherwise relinquish.

Business Risks
--------------

We are exposed to a variety of business risks, some of which are inherent to all
competitive commercial enterprises,  and others that are specific to the medical
products  industry.  We will  continue to endeavor  to limit all  specific  risk
factors by our operations and financial strategies.

Financial Risks
---------------

Our business  plans are  aggressive in nature.  Continued  rapid  expansion will
consume valuable working capital and result in significant  demand for cash from
operations  during  the next few  quarters.  We  expect  that  existing  capital
resources  and  contributions  from profits will not be  sufficient  to fund our
business plans as represented  without receiving  additional funds from external
sources.




<PAGE>



Business Cycles and Risks of Cost Overruns
------------------------------------------

The  sale  and  implementation  of our  products  involve  a  reasonable  market
penetration.  Failure to secure reasonable market penetration could have adverse
effects on our business, results of operations and its financial condition.

Fluctuations in Financial Results
---------------------------------

Our operating  results will  fluctuate,  depending on factors such as the demand
for products,  the size and timing of contracts,  new products and enhancements,
price  competition,  changes in  operating  expenses and  personnel  and general
economic factors.  Therefore,  actual financial  results may vary  significantly
from those projected by us.

Third-Party Claims for Infringement
-----------------------------------

We are not aware that any of our products infringe on the proprietary  rights of
third parties.  There can be no assurance,  however, that third parties will not
claim such  infringements by us with respect to current or future products.  Any
such claims,  with or without merit,  could be time consuming,  result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line
---------------------------------

Concentration  of sales in a single product line for the medical health industry
represents a substantial risk, should market conditions deteriorate.

Foreign Currency
----------------

Our business plans are primarily focused on the penetration in the United States
and subsequently worldwide markets; therefore, we will be subject to the risk of
foreign currency fluctuations.

Competition and Sales Channels
------------------------------

Several  companies  compete  with us in the  syringe  market and there are a few
competitors  in the safety syringe  market.  Most are  substantially  larger and
possess greater  financial  resources than we do. Our future  success,  however,
relies on achieving superior product development by greater concentration on the
needs of the market and faster response to evolving customer requirements. There
can be no  assurance,  however,  that  competitors  will  not  develop  products
superior to our products or achieve greater market  acceptance due to marketing,
sales channels or other factors.

Dependence on Large Distributors
--------------------------------

We will rely in part on business  partners for the distribution of our products.
This includes a few large  distributors in the United States. We may be impacted
by negative business cycles or events  experienced by these  distributors.  This
may result in a short or long term reduction in revenue.

Human Resource Risks and Growth
-------------------------------

Our  success is  largely  dependent  on the  performance  of its key  employees.
Failure to attract and retain key employees with necessary  skills could have an
adverse  impact upon our growth and  profitability.  Our business is expected to
increase  rapidly  during the next three  years.  This  increase  will result in
substantial  growth in the number of  employees,  the scope of our operating and
financial systems and the geographic area of our operations.  This increases the
responsibilities for both existing and new management personnel.  Our ability to
support the  projected  growth of our  business  will be  dependent  upon having
highly  trained  personnel  in place to conduct  pre-sales  activities,  product
implementation and other customer support services. Our future operating results
will  depend on the ability of our key  managers  and  employees  to continue to
implement and improve our operational,  customer support and financial  systems.
There can be no  assurance  that we will be able to manage any future  expansion
successfully,  and, if we cannot, this could adversely affect the results of our
operations and our financial condition.



<PAGE>



Production and Quality Control
------------------------------

The manufacturing of products involves a number of steps and requires compliance
with  stringent  quality  control   specifications  imposed  on  us  by  various
regulators.  We may not be able to replace manufacturing capacity quickly, if we
were unable to use our manufacturing  facilities as a result of a fire,  natural
disaster (including  earthquake),  equipment failure or other difficulty,  or if
such  facilities  are  deemed not in  compliance  with the  various  regulators'
requirements  and  the  non-compliance  could  not  be  rapidly  rectified.  The
inability or reduced  capacity to  manufacture or have  manufactured  any of our
products  would have a material  adverse  effect on the  business and results of
operations.

Government Standards and Regulations
------------------------------------

Our  products  will be subject to  numerous  foreign  government  standards  and
regulations  that are  continually  being amended.  Although we will endeavor to
satisfy foreign  technical and regulatory  standards,  there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes  thereto,  or that it will be cost effective to redesign our products
to  comply  with such  standards  or  regulations.  Our  inability  to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk
----------------------

Our  business  and the  business of our  subsidiary  will expose us to potential
product  liability  risks that are  inherent in the testing,  manufacturing  and
marketing  of medical  products.  We do not  currently  have  product  liability
insurance,  and  there  can be no  assurance  that we will be able to  obtain or
maintain such insurance on acceptable terms or, if obtained, that such insurance
will provide adequate coverage against potential liabilities.

We face an inherent  business  risk of exposure to product  liability  and other
claims,  in the event that the  development or use of our technology or products
is alleged to have  resulted  in adverse  effects.  That risk  exists  even with
respect to those  products  that are  manufactured  in  licensed  and  regulated
facilities or that otherwise  possess  regulatory  approval for commercial sale.
There can be no  assurance  that we will  avoid  significant  product  liability
exposure.  There can be no  assurance  that  insurance  will be available in the
future on commercially  reasonable terms, or at all, or that such insurance will
be  adequate  to pay  potential  product  liability  claims  or  that a loss  of
insurance  or the  assertion  of a product  liability  claim or claims would not
materially  adversely  affect our business,  financial  condition and results of
operations.

Although  we have  taken,  and  will  continue  to  take,  what we  believe  are
appropriate  precautions,   there  can  be  no  assurance  that  we  will  avoid
significant  liability  exposure.  An  inability  to  obtain  product  liability
insurance at acceptable cost or to otherwise  protect against  potential product
liability claims could prevent or inhibit the commercialization of our products.
A product  liability claim could have a material adverse effect on our business,
financial condition and results of operations.

Liquidity and Capital Resources
-------------------------------

We  believe we have  raised  enough  capital  to allow us to meet our  financial
obligations  for a period  of at least 3 months  from  February  28,  2003,  not
including  our  current  obligations,  aggregating  $158,334  under the  British
Columbia  Securities  Commission  rescission  offer.  However,  this three-month
forecast is a forward-looking  statement that involves risks and  uncertainties.
Actual results could differ  significantly as a result of these uncertainties as
the forecast assumes on-going support from creditors,  including the obligations
under the rescission offer, and shareholders.

We had cash  resources of $21,557 at February 28, 2003.  At May 31, 2002, we had
cash  resources of $142,114.  At February 28, 2003,  total  current  assets were
$48,355 and total current  liabilities of $321,384.  At February 28, 2003, total
current liabilities exceeded total current assets by $273,029.  At May 31, 2002,
total current assets were of $169,282 and total current liabilities of $319,537.
At May 31, 2002,  total current  liabilities  exceeded  total current  assets by
$150,255.  Because we are not generating any revenues,  our only external source




<PAGE>



of  liquidity  is  the  sale  of our  capital  stock.  We  have  no  contractual
obligations for capital  purchases or any other  commitments at this time, other
than an offer to purchase  additional  office space for  approximately  $604,000
with a planned  occupancy  date of April 1, 2003.  To date the  Company  has not
secured the necessary  financing to fund this acquisition and currently does not
expect to complete this acquisition.

Management's plans include  generating future profitable  operations from future
sales of the retractable syringe as well as additional funding from stockholders
in the form of additional share subscriptions.  There can be no assurance that a
market  will  develop  for the  retractable  syringe  or that  additional  share
financings will be available.  Failure to obtain  adequate  financing will cause
the Company to curtail operations.

Critical Accounting Policies
----------------------------

The Company's  discussion and analysis of its financial condition and results of
operations,  including the  discussion on liquidity and capital  resources,  are
based upon the  Company's  financial  statements,  which have been  prepared  in
accordance with accounting  principles  generally accepted in the United States.
The  preparation  of these  financial  statements  requires  the Company to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues  and  expenses,   and  related  disclosure  of  contingent  assets  and
liabilities.  On an ongoing  basis,  management  re-evaluates  its estimates and
judgments.  Actual results could differ from the estimates. The Company believes
the following critical accounting policy requires more significant  judgment and
estimates used in the preparation of the consolidated financial statements.

The  consolidated  financial  statements have been prepared on the going concern
basis, which assumes the realization of assets and liquidation of liabilities in
the normal course of operations.  If the Company were not to continue as a going
concern,  it  would  likely  not be able to  realize  on its  assets  at  values
comparable to the carrying  value or the fair value  estimates  reflected in the
balances set out in the preparation of the consolidated financial statements. As
described  elsewhere  in this  report,  at  February  28, 2003 there are certain
conditions that currently exist which raise substantial doubt about the validity
of this assumption.  While the Company  anticipates  raising  additional funding
through  future  profitable  operations and the sale of share  subscriptions  to
remove the  substantial  doubt,  these funds are not  assured.  Failure to raise
additional  funds may result in the  Company  curtailing  operations  or writing
assets and liabilities down to liquidation values, or both.

Results of Operations
---------------------

We have not yet realized any revenues from  operations.  The loss from March 17,
1997 (inception) to February 28, 2003, was $4,655,559.  The loss for the 9-month
period ended February 28, 2003, was $721,331  compared to a loss of $834,831 for
the 9-month  period  ended  February 28, 2002.  Such losses were  primarily  the
result of product development and operational expenditures.

In the current  3-month  period the loss,  before  compensation  cost of options
granted to  non-employees  of  $191,450,  has  decreased  compared  to the prior
comparable  period  because we are  restricting  outflow of funds  until we have
additional  capitalization.  During the 9-month period ending February 28, 2003,
we have paid  $75,556  with  regards to  developing  the  Syringe  and the Blood
Collection  units,  compared to $383,163  incurred  during the  9-months  ending
February 28, 2002.  General and  administrative  expenses for the 9-month period
ending  February 28, 2003 have  remained  similar to the 9-month  period  amount
ending  February  28, 2002 except for  compensation  cost of options  granted to
non-employees during the 9 months ended February 28, 2003.

For the 9-month  period ended  February 28, 2003,  capital stock and  additional
paid-in  capital  have  increased  by  $604,191  since  May 31,  2002 due to the
conversion of stock  subscriptions  to common  shares,  a beneficial  conversion
option on convertible promissory notes,  compensation cost of options granted to
non-employees and the issuance of common shares for cash and services.



<PAGE>



Item 3.  Controls and Procedures
--------------------------------

The company  maintains  disclosure  controls and procedures that are designed to
ensure that information  required to be disclosed in the Company's reports filed
pursuant to the  Securities  Exchange Act of 1934 are recorded,  processed,  and
summarized and reported within the time periods specified in the rules and forms
promulgated  under  such  Act,  and that such  information  is  accumulated  and
communicated to the Company's management,  including the Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure.

Within  the 90 days  prior  to the  date of this  report,  the  Company's  Chief
Executive Officer and Chief Financial  Officer,  with the participation of other
members of  management,  carried out an evaluation of the  effectiveness  of the
design  and  operation  of the  Company's  disclosure  controls  and  procedures
pursuant to Exchange  Act Rule 13a-14 of the  Securities  Exchange  Act of 1934.
Based upon that  evaluation,  the Chief  Executive  Officer and Chief  Financial
Officer  concluded that the disclosure  controls and procedures are effective in
connection  with the  filing of this  Quarterly  Report on Form  10-QSB  for the
quarter ended February 28, 2003.

There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
our most recent evaluation,  including any significant deficiencies and material
weaknesses of internal controls that would require corrective action.






<PAGE>



                                     Part II
                                     -------


Item 1.  Legal Proceedings
--------------------------

Litigation Involving Our Subsidiary.
------------------------------------

None

British Columbia Securities Commission Rescission Offer.
--------------------------------------------------------

As of February 28, 2003,  stockholders holding 67,570 shares of our common stock
with a paid up capital of $204,560 have exercised their right of rescission.  As
of February 28, 2003,  $46,226 had been paid  regarding  the  rescission  offer,
leaving  $158,334  remaining to be paid, which has been recorded in our accounts
payable and accrued liabilities.

Item 2.  Changes in Securities
------------------------------

Warrants.
---------

We have offered to all  shareholders of record at June 30, 2001, one warrant for
every 2 shares held by each  shareholder.  Each  warrant  entitles the holder of
such warrant to purchase one share of our common stock for $5.00 per share. Each
warrant  expires 90 days after the first  transaction in our common stock occurs
on a public market

Stock Options.
--------------

Our Board of Directors  has adopted a stock option plan ("Stock  Option  Plan").
The Stock Option Plan is designed to retain  qualified and  competent  officers,
employees and directors of the Company.  Our Board of Directors,  or a committee
thereof,  shall administer the Stock Option Plan and is authorized,  in its sole
and absolute  discretion,  to grant  options to all of our  eligible  employees,
officers and  directors  (whether or not employed by us).  During the year ended
May 31, 2001,  340,417 and during the nine month period ended February 28, 2003,
359,833  stock  options were granted in  accordance  with the Stock Option Plan.
Under  SFAS 123,  compensation  cost of  $486,719  has been  recorded  for those
options issued to consultants to February 28, 2003.  Options granted pursuant to
the Stock  Option Plan will be  exercisable  within the period  specified in the
respective stock option agreements.  Options granted under the Stock Option Plan
will not be exercisable  after the expiration of ten (10) years from the date of
grant  for  shareholders  with less  than 10%  ownership  and five (5) years for
shareholders with 10% or more share ownership.

Share Issuances.
----------------

During the three months  ended  February 28,  2003,  16,268  common  shares were
issued  pursuant  to  Regulation  S at a  purchase  price of $3.25  per share on
conversion of stock  subscriptions  received prior to November 30, 2002, and 323
common shares were issued  pursuant to Regulation S at a purchase price of $2.00
per share on conversion of convertible promissory notes.  Subsequent to February
28, 2003, 2,500 common shares were issued pursuant to Regulation S at a price of
$3.25 per share for  subscriptions  received  prior to February 28, 2003 and 324
common  shares  were  issued  at a price of $2.00  per  share on  conversion  of
convertible promissory notes.

Item 3.  Default Upon Senior Securities
---------------------------------------

None.

Item 4.  Submission of Matters to Vote of Security Holders
----------------------------------------------------------

None



<PAGE>



Item 5.  Other Information
--------------------------

None

Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------

Dr.  Punnet  resigned as a director  effective  April 16, 2002.  Peter  McFadden
resigned as CFO and Vice President  effective  August 15th 2002.  Tanya Sedlacek
became CFO on August 15th 2002.




<PAGE>




                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:   April 11, 2003                   L.O.M. Medical International, Inc.


                                          By:    /s/ John Klippenstein
                                             -----------------------------------
                                                 John Klippenstein
                                          Its:   President


                                          By:    /s/ Tanya Sedlacek
                                             -----------------------------------
                                                 Tanya Sedlacek
                                          Its:   Chief Financial Officer



<PAGE>



                                 CERTIFICATIONS

I, John Klippenstein, certify that:

1.   I have  reviewed  this  quarterly  report on Form 10-QSB of L.O.M.  Medical
     International Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officer  and  I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     c)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     d)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     e)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's  other certifying  officer and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of the registrant's board of directors (or persons performing the
     equivalent function):

     c)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     d)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officer and I have  indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: April 11, 2003



/s/ John Klippenstein
-----------------------------------------------
John Klippenstein, President & CEO



<PAGE>



                                 CERTIFICATIONS

I, Tanya Sedlacek, certify that:

7.   I have  reviewed  this  quarterly  report on Form 10-QSB of L.O.M.  Medical
     International Inc.;

8.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

9.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

10.  The  registrant's  other  certifying  officer  and  I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     c)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     d)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     e)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

11.  The registrant's  other certifying  officer and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of the registrant's board of directors (or persons performing the
     equivalent function):

     c)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     d)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

12.  The  registrant's  other  certifying  officer and I have  indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: April 11, 2003



/s/ Tanya Sedlacek
--------------------------------
Tanya Sedlacek, CFO